

Do not enter.
GN 02/04/2004

In The Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

Claims 1-71 (canceled)

Claim 72 (previously presented): A method for inhibiting the growth, viability and/or survivability of cancer cells that express the nucleotide sequence SEQ. ID. No.: 1 or the cDNA in ATCC deposit 207097 (20P1F12/TMPRSS2), the method comprising:

administering to the cancer cells an antibody or fragment thereof that specifically binds to a 20P1F12/TMPRSS2 protein, thereby inhibiting the growth, viability and/or survivability of said cancer cells.

Claim 73 (previously presented): The method of claim 72, wherein said antibody or fragment is a monoclonal antibody, or fragment thereof.

Claim 74 (previously presented): The method of claim 72, wherein said antibody or fragment is a recombinant protein comprising the antigen-binding region of an antibody that specifically binds to 20P1F12/TMPRSS2 protein.

Claim 75 (previously presented): The method of claim 72, wherein said antibody or fragment is labeled with a detectable marker.

Claim 76 (previously presented): The method of claim 72, wherein said antibody or fragment is conjugated with a cytotoxic agent.

Claim 77 (previously presented): The method of claim 72, wherein said antibody or fragment is a human antibody or fragment.